Chronic Pain Patient Articles & Analysis
24 news found
“Approximately 50 million individuals in the United States suffer from chronic pain; unfortunately, many of these patients have limited treatment options that are safe or well tolerated and live with life-impacting pain that is not well managed. ...
The epidural injection site will vary depending on the patients’ needs. Most spinal injections specifically are performed as a portion of a more comprehensive treatment program, aiming to boost spinal mobility and cure the patient of chronic pain levels. ...
Nine patients will take part in this experimental treatment, wherein patients will receive ICV administration of valproate via the Flowonix Prometra II Programmable Pump. ...
I believe Nalu’s unique system and technology, including the miniaturized, battery-free implantable pulse generator with its broad capabilities, upgradability and industry leading longevity are going to meaningfully expand the number of chronic pain patients who can benefit from both Spinal Cord and Peripheral Nerve Stimulation. ...
Excite Medical, the leading provider of non-surgical spinal decompression machines for back pain and neck pain, recently showcased its innovative and groundbreaking DRX9000® spinal decompression machine at the Florida Chiropractic Association’s (FCA) Northeast Regional Convention and Expo, held at the World Golf Renaissance in St. ...
“Modulating stimulation pulse width has the potential to selectively recruit particular nerve fibers that could benefit patients with difficult to address pain patterns. With the introduction of a pulse width expanded to 2,000 microseconds, I now have one more tool to help address the short- and long-term pain relief needs of individual ...
SENZA-NSRBP Randomized Controlled Trial Results Show Profound Improvements in Non-Surgical Refractory Back Pain Patients Receiving 10 kHz Therapy Relative to Conventional Medical Management at 12-Months Follow-Up. ...
The two-year results demonstrate that Evoke closed-loop 12-month superior pain relief results were sustained out to 24 months and that Evoke closed-loop patients exhibit greater long-term improvements in patient-reported outcomes than open-loop patients, with quality-of-life improvements nearing normative values for the U.S. ...
Nalu is a California-based company with miniaturized, commercially available neurostimulation implants for chronic intractable pain management. Nalu’s miniature implantable pulse generator (IPG) is 27 times smaller than the largest commercially available IPGs. ...
Nalu is a California-based company with miniaturized, commercially available neurostimulation implants for chronic intractable pain management. Nalu’s miniature implantable pulse generator (IPG) is 27 times smaller than the largest commercially available IPGs. ...
There is a high unmet medical need in chronic pain, particularly among patients with concomitant opioid use problems. ...
The Nalu mIPG, was recognized by the judges for its creative and innovative application of technology to treat chronic intractable pain. Using advanced miniaturization and by eliminating the internal chemical battery in the implantable component, the Nalu mIPG is 27 times smaller than the largest commercially available implantable pulse generators (IPG).1 Its ...
The campaign highlights the award-winning engineering design of its Nalu micro-Implantable Pulse Generator (mIPG) and how the Nalu neurostimulation system is engineered to address major unmet needs in the management of intractable chronic pain and provide a differentiated value proposition for patients and physicians. ...
The publication, titled “Neuromodulation using ultra low frequency current waveform reversibly blocks axonal conduction and chronic pain,” was a collaboration spanning three continents, and describes groundbreaking research on how ULF™ neuromodulation inhibits pain signals in pre-clinical animal models, computational models, and ...
(“Nalu”), a California-based company that has successfully miniaturized neurostimulation implants for chronic intractable pain management indications, announced that the scientific presentation schedule during the 2021 North American Neuromodulation Society (NANS) Mid-Year Meeting in Orlando, Florida will include three abstract submissions all ...
“With this latest upgrade, we offer an expanded menu of therapy options to help people suffering with intractable chronic pain to better configure their therapies according to their preferences and within clinician-defined ...
Results show ~90% overall back and leg responder rate, ~68% high responder rate, and zero explants due to loss of efficacy ~83% of patients reduced or eliminated opioid use Need for patient re-programming visits nearly eliminated after 12 months Represents the first peer reviewed SCS study to show responder and high responder rate improvement over time Saluda ...
Saluda Medical Pty Limited (“Saluda Medical”), the market leader in the development of novel closed-loop spinal cord stimulation (SCS) for the treatment of chronic pain, today announced the appointment of Jim Schuermann as President & Chief Executive Officer. ...
(NYSE: NVRO), a global medical device company that is providing innovative, evidence-based solutions for the treatment of chronic pain, today announced the results from data presentations at NANS supporting the use of HF10® therapy for patients with chronic pain, including results from the ...
(NYSE: NVRO), a global medical device company that is providing innovative, evidence-based solutions for the treatment of chronic pain, today announced a series of data presentations supporting the use of the company's HF10® therapy for patients with chronic pain. ...